References
- Thomas SK. Waldenstrom Macroglobulinemia —- 2021 update on management and future directions. Clin Lymphoma Myeloma Leuk. 2021: S2152-2650(21)02447-2.
- Baďurová K, Gregorová J, Vlachová M, Krejčí M, Ševčíková S. Waldenstrom macroglobulinemia. Klin Onkol. 2021;34(6):428–33.
- Gertz MA. Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96(2):258–69.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
- Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc. 2013;55(1):75–83.
- Consuegra A, PJ Marcos, R Vazquez, Pombo J, Deben G, Verea-Hernando H. Diffuse interstitial lung disease as a first manifestation of Waldenström macroglobulinemia: case report and review of the literature. Arch Bronconeumol. 2014;50(4):151–3.
- Green AP, Gonzalez AC, Alperin JB, Burner JD, Yates SG. The utility of therapeutic plasma exchange in hyperviscosity syndrome associated with juvenile rheumatoid arthritis: A case report. J Clin Apher. 2021;36(4):658–63.
- Hernández-Molina G, Bermúdez-Bermejo P. Hyperviscosity in primary Sjogren's syndrome: clinical implications. Int J Rheum Dis. 2017;20(1):84–9.
- Schatz MJ, Wilkins CS, Otero-Marquez O, Chui TYP, Rosen RB, Gupta M. Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis. Case Rep Ophthalmol Med. 2021;2021:6816195.
- Kikukawa Y, Yamamura-Fujimoto A, Endo S, Miyagawa E, Kawano Y, Ueno S, Mitsuya H, Hata H, Okuno Y. Successful treatment of Bing-Neel syndrome accompanying Waldenstrom's macroglobulinemia with R-MPV: a case report. J Clin Exp Hematop. 2015;55(2):113–9.
- Kudo N, Usui M, Nakabo Y, Yoshida KI, Miki K, Osafune T, Nishimura K, Imashuku S. Waldenstrom's macroglobulinemia: a report of two cases, one with severe retinopathy and one with renal failure. Case Rep Hematol. 2017;2017:3732902.
- Mihalcea DJ, Florescu M, Vinereanu D. Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer. Am J Ther. 2017;24(1):e3–e11.
- Mihalcea D, Florescu M, Bruja R, Patrascu N, Vladareanu AM, Vinereanu D. 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma. Sci Rep. 2020;10(1):18473.
- Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83–92.
- Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801.
- Pancheri E, Guglielmi V, Wilczynski GM, Malatesta M, Tonin P, Tomelleri G, Nowis D, Vattemi G. Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects. Cancers (Basel). 2020;12(9):2540.
- Atalay F, Gulmez O, Ozsancak Ugurlu A. Cardiotoxicity following cyclophosphamide therapy: a case report. J Med Case Rep. 2014;8:252.
- Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, Morioka S, Furukawa Y. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330–4.
- de Salvi Guimarães F, de Moraes WM, Bozi LH, Souza PR, Antonio EL, Bocalini DS, Tucci PJ, Ribeiro DA, Brum PC, Medeiros A. Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation. Mol Cell Biochem. 2017;424(1–2):87–98.
- Ng KH, Dearden C, Gruber P. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep. 2015;2015:bcr2014208203.
- Lazarevic VLj, Liljeholm M, Forsberg K, Söderberg S, Wahlin A. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1209–11.
- Montrone D, Correale M, Franzese MG, Ieva R, Di Biase M, Capalbo SF. Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab. J Cardiovasc Med (Hagerstown). 2015;16 Suppl 1:S65.